Skip to content
value.today

Galecto Inc.

🇩🇰 Copenhagen, Denmark, DenmarkPharmaceuticalsFounded 2019
Total raised
$64 M
1 round on record
Latest round
$64 M
Sep 2020
First round on record
Sep 2020
Today
Went public
See the company page

Galecto Inc. is listed today as Damora Therapeutics, Inc.: market value, financials and filings are on its company page.

Funding rounds

1 counted as startup funding, 2 other private sales on record. Open the number of investors for the round's details.

Funding rounds of Galecto Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Nov 2025$285 MPrivate placement after listing$250 million to $1 billion

Galecto Inc.: Private sale, Nov 2025

Investors in this round

48 investors had bought by the notice of Nov 21, 2025: 48 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 14 investors are named for Galecto Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$285 M of $285 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
$17,100,000
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Garrett T. Winslow · Executive Officer
  • Hans T. Schambye · Executive Officer, Director
  • Lori T. Firmani · Executive Officer
  • Amit T. Munshi · Director
  • Carl T. Goldfischer · Director
  • Christopher T. Cain · Director
  • Jayson T. Dallas · Director
  • Julianne T. Bruno · Director
  • Peter T. Harwin · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • UBS Securities LLC (CRD 7654) · New York, New YorkSold in CA, CO, CT, DE, GA, IL, MA, NJ, NY, PA, TX
  • Leerink Partners LLC (CRD 39011) · New York, New YorkSold in CA, CO, CT, DE, GA, IL, MA, NJ, NY, PA, TX
  • LifeSci Capital, LLC (CRD 168404) · New York, New YorkSold in CA, CO, CT, DE, GA, IL, MA, NJ, NY, PA, TX
  • Jefferies LLC (CRD 2347) · New York, New YorkSold in CA, CO, CT, DE, GA, IL, MA, NJ, NY, PA, TX

Signed by Hans T. Schambye, President & Chief Executive Officer. Source: SEC Form D, newest notice filed Nov 21, 2025. Read the notice at the SEC.

equitySEC
Sep 2020$64 MNo. 1$50 to $250 million

Galecto Inc.: Raise no. 1, Sep 2020

Investors in this round

42 investors had bought by the notice of Nov 5, 2020: 42 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 14 investors are named for Galecto Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$64 M of $64 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Hans Schambye · Executive Officer, Director
  • Jon Freve · Executive Officer
  • Amit Q. Munshi · Director
  • Carl Q. Goldfischer · Director
  • Chandra Q. Leo · Director
  • Chao Q. Khuong · Director
  • David Q. Shapiro · Director
  • Erez Q. Chimovits · Director
  • Karen Wagner · Director
  • Soren Q. Lemonius · Director
  • Soren Q. Moller · Director
  • Stephan Q. Christgau · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Hans Schambye, President & CEO. Source: SEC Form D, newest notice filed Nov 5, 2020. Read the notice at the SEC.

equitySEC
Dec 2019$79 MIssued in a merger or acquisition$50 to $250 million

Galecto Inc.: Private sale, Dec 2019

Investors in this round

35 investors had bought by the notice of Jan 16, 2020: 25 accredited, 10 not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 14 investors are named for Galecto Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$79 M of $124 M offered; $45 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Hans Schambye · Executive Officer
  • Jakob Dynnes Hansen · Executive Officer

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Hans Schambye, Ceo. Source: SEC Form D, newest notice filed Jan 16, 2020. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Galecto Inc. chose not to state its revenue in its newest notice of a funding round (Nov 2025).

    SEC Form D · Nov 2025

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Nov 2025

That is all the official record says: Galecto Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services of Galecto Inc. are on record.

Investors#

14 named in official filings. Open an investor to see everything it has backed.

Investors in Galecto Inc.
InvestorKindAmountRoundRoleSource
Amit MunshiPersonnot statednot statedHeld Series D preferred stock, director (Form 3, 2020)SEC Form 3
Anders PedersenPersonnot statednot statedHeld Series C-1 preferred stock (Form 3, 2020)SEC Form 3
Carl GoldfischerPersonnot statednot statedHeld Series D preferred stock, director (Form 3, 2020)SEC Form 3
Fairmount Funds Management LLCFund or asset managernot statednot statedHeld Series B and C preferred stock, 10% owner, director (Form 3, 2025)SEC Form 3
Fairmount Healthcare Co-Invest V L.P.Fund or asset managernot statednot statedHeld Series B and C preferred stock, 10% owner (Form 3, 2025)SEC Form 3
Fairmount Healthcare Fund II L.P.Fund or asset managernot statednot statedHeld Series B and C preferred stock, 10% owner (Form 3, 2025)SEC Form 3
Hans T. SchambyePersonnot statednot statedHeld Series C-1 preferred stock, director (Form 3, 2020)SEC Form 3
Julianne BrunoPersonnot statednot statedHeld Series C preferred stock, director (Form 3, 2025)SEC Form 3
Novo Holdings A/sFund or asset managernot statednot statedHeld Series B-1, B-2, B-3, B-4, C-1, C-2, C-4, C-5 and D preferred (Form 3, 2020SEC Form 3
OrbiMed Advisors Israel II LtdFund or asset managernot statednot statedHeld Series C-2, C-4, C-5 and D preferred (Form 3, 2020)SEC Form 3
Orbimed Advisors LLCFund or asset managernot statednot statedHeld Series C-2, C-4, C-5 and D preferred (Form 3, 2020)SEC Form 3
OrbiMed Capital GP VII LLCFund or asset managernot statednot statedHeld Series C-2, C-4, C-5 and D preferred (Form 3, 2020)SEC Form 3
OrbiMed Genesis GP LLCOthernot statednot statedHeld Series C-2, C-4, C-5 and D preferred (Form 3, 2020)SEC Form 3
OrbiMed Israel GP II, L.P.Fund or asset managernot statednot statedHeld Series C-2, C-4, C-5 and D preferred (Form 3, 2020)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 42 investors.

Largest shareholders today

Institutions holding Damora Therapeutics, Inc. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Galecto Inc.
NameRoleNamed in
Garrett T. WinslowExecutive officerNov 2025
Hans T. SchambyeExecutive officerNov 2025
Lori T. FirmaniExecutive officerNov 2025
Hans SchambyeExecutive officerNov 2020
Jon FreveExecutive officerNov 2020
Jakob Dynnes HansenExecutive officerJan 2020
Amit T. MunshiDirectorNov 2025
Carl T. GoldfischerDirectorNov 2025
Christopher T. CainDirectorNov 2025
Hans T. SchambyeDirectorNov 2025
Jayson T. DallasDirectorNov 2025
Julianne T. BrunoDirectorNov 2025
Peter T. HarwinDirectorNov 2025
Amit Q. MunshiDirectorNov 2020
Carl Q. GoldfischerDirectorNov 2020
Chandra Q. LeoDirectorNov 2020
Chao Q. KhuongDirectorNov 2020
David Q. ShapiroDirectorNov 2020
Erez Q. ChimovitsDirectorNov 2020
Hans SchambyeDirectorNov 2020
Karen WagnerDirectorNov 2020
Soren Q. LemoniusDirectorNov 2020
Soren Q. MollerDirectorNov 2020
Stephan Q. ChristgauDirectorNov 2020

Went public since 2020. Its SEC number is that of a company listed on a stock exchange.